1. Диагностика и лечение артериальной гипертензии. Третий пересмотр рекомендаций ВНОК и РМОАГ. Кардиоваскулярная терапия и профилактика 2008; 7(6) приложение 2: 1-32.
2. Диагностика и лечение хронической сердечной недостаточности. Национальные рекомендации ВНОК и ОССН (второй пересмотр). Сердечная недостаточность 2007; 8(2):1-35.
3. Yusuf S., Sleight P., Pogue J. et al. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342(3):145-53.
4. Dagenais G.R., Yusuf S., Bourassa M.G. et al. Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation 2001;104(5):522-526.
5. Bosch J., Yusuf S., Pogue J. et al. Use oframipril in preventing stroke: double blind randomised trial. BMJ 2002;324(7339):699-702.
6. Fox K.M.; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable co�ronary artery disease:randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9386); 782-788.
7. Bonner G., Preis S., Schunck U. et al. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol 1990; 15 Suppl 6:S46-56.
8. Busse R., LamontagneD. Endothelium–derived bradykinin is responsible for the increase in calcium produced by angiotensin–converting enzyme inhibitors in human endothelial cells. Naunyn Schmiedebergs Arch Pharmacol 1991;344(1):126-9.
9. Anderson T.J., Overhiser R.W., Haber H., Charbonneau F. A comparative study of four anti–hypertensive agents on endothelial function in patients with coronary disease. J Am Coll Cardiol 1998;31 (2 suppl A):327A. Abstract.
10. Braunwald E., Domanski M.J., Fowler S.E. et al. PEAСE Trial investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351(20): 2058-2068.
11. Nissen S.E., Tuscu E.M., Libby P. et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary artery disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004; 292(18): 2217-2226.
12. Диагностика и лечение стабильной стенокардии. Рекомендации ВНОК (второй пересмотр). В Оганов Р.Г., Мамедов М.Н., редакторы. Национальные клинические рекомендации. М.: МЕДИ Экспо; 2009. стр 37-76.
13. Lonn E.M., Yusuf S., Dzavic V. et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001:103(7):919-25.
14. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society ofHypertension (ESH) and ofthe European Society of Cardiology (ESC). J Hypertens 2007;25(6):1105-87.
15. Effects oframipril on cardiovascular and microvascular outcomes in people with diabetes mellitus:results oftheHOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200): 253-259.
16. Agodoa L.Y., Appel L., Bakris G.L. et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001;285(21):2719-28.
17. Колос И.П., Мартынюк Т.В., Сафарян А.С. и др. Изучение эффективности терапии ингибитором ангиотензин-превращающего фермента рамиприлом и его комбинации с гидрохлортиазидом у пациентов с артериальной гипертонией и избыточной массой тела: исследованиеХАРИЗМА.Кардиоваскулярная терапия и профилактика 2008;7(2):65-71.
